INTRODUCTION
Approximately 15% of newly diagnosed male cancer patients are less than 55 years of age at diagnosis, and approximately 26% of these patients less than 20 years of age. 1, 2 Acute lymphoblastic leukemia and brain tumors are the most frequently occurring malignancies in children aged 15 years or younger, whereas malignant lymphoma, testicular cancer, lung cancer and malignant melanoma are most common among males aged 15-54 years. The 5-year survival rate for male cancer patients below the age of 15 years approaches 75%, 3 and for those aged 15-44 years the 5-year relative survival rate is 61%. 4 For many of these men, the question arises: how will the malignancy or its treatment affect future fertility? This could also be relevant for some older men with younger wives, who might have plans for parenthood. Registered data indicate that the 15-year cumulative probability of post-treatment paternity is approximately 32% in cancer patients diagnosed between the ages of 15 and 45 years ( Figure 1 ). 5 Male subfertility and infertility can be caused by somatic or psychosocial factors. This review deals with the somatic aspects of prevention and treatment of infertility in male cancer patients, discussing the roles that surgery, radiotherapy and chemotherapy play in inducing changes that lead to infertility.
PHYSIOLOGY OF MALE FERTILITY
Normal fertility requires undisturbed spermatogenesis, undisturbed transport of the mature sperm cells, and antegrade ejaculation. The production of mature sperm cells, starting from the stem cells of the germinative epithelium (spermatogonia), takes approximately 70 days. 6 This process is dependent on the hypothalamicpituitary-gonadal axis functioning normally. At the testicular level, luteinizing hormone (LH) regulates testosterone production by the Leydig cells. 6 Follicle-stimulating hormone (FSH) and testosterone stimulate the Sertoli cells, which provide both physical and nutritional resources for In male cancer patients, surgery, radiotherapy and chemotherapy can be followed by transient or permanent infertility by affecting ejaculatory or erectile function, or by impairing spermatogenesis. Cancer specialists should, therefore, discuss the impact of different therapies on fertility with their patients prior to treatment, and consider fertility-preserving measures before and during treatment, such as nerve-sparing operative techniques, adequate testicular shielding during radiotherapy and the avoidance of unnecessary gonadotoxic chemotherapy. Pretreatment spermcell cryopreservation should be offered, even in cases where the individual's risk of post-treatment infertility might seem minimal or if it might require testicular sperm-cell extraction. Samples that are severely oligospermic should also be cryopreserved. Post-treatment ejaculatory or erectile dysfunction can be reversed pharmacologically, but the success rate varies with the extent of neurologic sequelae of the treatments used. At present there is no established method to stimulate post-treatment impaired spermatogenesis, although currently available assisted reproductive techniques overcome some of the existing problems of infertility in cancer survivors, and ongoing research will hopefully increase these possibilities. A multidisciplinary approach that depends on close cooperation between relevant medical specialists is central to achieving such advances. spermato genesis. 6, 7 Sertoli cells secrete inhibin B, which controls FSH secretion through a negativefeedback mechanism. 6 Any disruption in levels of these hormones can interrupt these mechanisms and lead to impaired spermatogenesis. Table 1 shows the normal levels of these hormones. Impaired spermatogenesis (identified by reduced sperm-cell concentration in the ejaculate, reduced sperm-cell motility or abnormal sperm morphology) 8 is reflected by elevated serum levels of FSH and low levels of inhibin B, if caused by primary testicular failure, 9 with normal or low levels of testosterone. Low serum FSH and low serum LH, combined with azoospermia, indicate a pituitary cause, and these patients should be referred to an endocrinologist. Azoospermia combined with normal serum gonadotropin levels points to disturbed transport of the sperm cells because of obstruction of the structures that normally transport sperm cells, or disturbed innervation of emission or ejaculation. 6, 10 Erectile dysfunction (ED) also results in fertility problems. 11 Cancer and its treatment can affect all of the pathways involved in male reproductive function, thereby leading to impaired fertility.
FERTILITY PROBLEMS RELATED TO THE MALIGNANT PROCESS
Testicular cancer is the only malignancy where there is evidence of a shared etiology for the malignant process and reduced fertility, as part of the TESTICULAR DYSGENESIS SYNDROME (TDS). 12 This syndrome is most probably the result of disturbed male gonadal development during early embryonic life, the result of environmental factors and genetically programmed susceptibility. 12 Animal experiments have shown that prenatal exposure to endocrine disrupters (estrogen and antiandrogenlike agents) negatively affects the differentiation of the Sertoli cells and Leydig cells, causing disturbed germ-cell proliferation and reduced testosterone production. These defects in gonadal development can also manifest as hypospadias, undescended testis and intersex conditions in newborn animals. Mutations or polymorphisms of the estrogenregulated insulin-like factor 3 gene might be involved in disturbed development of the gubernaculum, 13 thus representing an additional link for the involvement of endocrine disrupters in the development of cryptorchidism.
The mildest form of TDS in humans is probably characterized by impaired spermatogenesis only, and might, in addition to other factors, explain unwanted childlessness in one out of every six couples, as is observed in the general population. 14 The simultaneous presence of impaired spermatogenesis with either cryptorchidism or hypospadias indicates more severe forms of TDS. The risk of developing testicular cancer rises with increasing TDS severity. Theoretically, TDS developing in the fetus affects both testes; thus explaining the morphologic and functional disturbances, mirrored by low sperm counts, that are frequently observed in the contralateral testes of men after orchiectomy for unilateral testicular cancer. A Danish group reported that the median sperm count in testicular-cancer patients before orchiectomy was 17 × 10 6 sperm/ml, 15 which is about a third of the level observed in the general adult male population. Infertile men should always be examined for testicular cancer. Studies have reported that 0.3-1.1% of infertile men have been diagnosed with testicular cancer or its premalignant precursor, carcinoma in situ, which is at least 10 times the incidence observed in the general male population aged 20 to 40 years. 16, 17 Furthermore, biopsies have revealed that 24% of patients with unilateral testicular cancer probably have irreversibly impaired spermatogenesis in the contralateral testicle. 18 In addition to these intrinsic factors, disturbances of the hypothalamic-pituitary-gonadal axis can be caused by hormonal imbalances. For example, hormonal imbalances can be induced by production of human choriogonadotropin in the malignant tissue, subsequently leading to increased serum estrogen levels, and thereby suppressing spermatogenesis. 19 Hodgkin's lymphoma is also associated with subfertility, and pretreatment impaired spermatogenesis has been reported in about two out of every three male patients, of which about half had low sperm counts. 20, 21 The presence of B SYMPTOMS, such as fever, night sweats and weight loss, or advanced stages of disease (stages III and IV), are thought to be negative prognostic factors for pretreatment fertility. 20, 21 The exact mechanism of impaired spermato genesis associated with Hodgkin's lymphoma is not known, but it is not thought to be a result of primary gonadal damage. 21 Cytokines have attracted some interest as a possible contributing factor to reduced fertility. 20 Infertility resulting from antisperm antibodies seems to be of only limited significance in testicular-cancer patients. Although a higher than normal incidence of such antibodies can be found in these patients, this is only associated with abnormal sperm characteristics in some. 22 
THE EFFECT OF CANCER TREATMENTS ON FERTILITY Surgery
Cancer surgery affecting the genital or pelvic organs can have adverse consequences for fertility. After unilateral orchiectomy in testicular cancer patients, sperm-cell concentrations are reduced compared to presurgery concentrations. 15 Bilateral, radical retroperitoneal lymph-node dissection (RPLND) leads to DRY EJACULATION in almost 100% of patients, as a result of the resection of postganglionic nerves of the hypogastric plexus, from which nerves descend into the pelvis and innervate the pelvic organs. 10 Since the introduction of unilateral RPLND, early in the 1980s, 23 and the development of nerve-sparing techniques, 10 the incidence of postoperative dry ejaculation has been reduced to only 10%, even if RPLND is done following induction chemotherapy.
Radical prostatectomy performed in prostatecancer patients, either on its own or combined with total cystectomy in bladder cancer patients, leads to ED in 30-80% of patients. The risk of developing postprostatectomy ED is dependent on a number of factors and, therefore, is influenced by patient selection. Factors such as the patient's age and comorbidities, the type of assessment of ED, and whether or not the neurovascular bundle can be spared unilaterally or bilaterally all contribute to the risk of developing post prostatectomy ED. 11, 24 Younger men are, for example, more likely to regain erectile function after prostatectomy. 25 Furthermore, recorded percentages of erectile function depend on whether or not one considers erectile function as normal in patients using phospho diesterase type 5 (PDE5) inhibitors. After surgery for cancer of the rectum, 20-40% of male patients develop complete ED and 16% of patients suffer from postoperative ejaculatory dysfunction. 26 
Radiotherapy
High-dose radiotherapy to the pelvic region is an important treatment modality in patients with cancer of the prostate, 27 rectum 28 and bladder. 29 Furthermore, radiotherapy has a place in organconserving treatment of early penile cancer. When radiotherapy was used in patients with early-stage penile cancer, erectile function was preserved in approximately 50% of patients. 30 INFRADIAPHRAGMATIC RADIOTHERAPY is still the standard treatment for many patients with testicular seminoma tumors. 31 Fractionated testicular irradiation at target doses of 20 Gy leads to permanent azoospermia. This treatment is usually given to patients with carcinoma in situ of the testis 31, 32 or as an adjuvant treatment after testis-conserving surgery of a small-sized testicular cancer. 31 Although Leydig cells are relatively radioresistant, such radiotherapy might be followed by a reduction in testosterone production, and testosterone supplementation is necessary in approximately 40% of patients with unilateral testicular cancer in whom the remaining testicle is irradiated because of carcinoma in situ. 32 Pelvic external-beam radiotherapy for prostate, bladder and rectal cancer has resulted in scattered testicular doses of 0.4-18.7% of the prescribed radiation dose. 33, 34 When different types of abdominopelvic radiotherapy are compared, the highest scattered doses reaching the testes are seen in patients treated for rectal cancer. This exposure puts patients at a high risk of developing permanent infertility. During the first 12 months following radiotherapy with 50 Gy for rectal cancer (which resulted in testicular doses of 0.7-8.4 Gy), patients' FSH levels have been shown to increase by 85% and testosterone levels to decrease by 22%. 34 Spermatogenesis seems to be only minimally inhibited after brachytherapy of prostate cancer, as the scattered irradiation dose usually does not exceed 20 cGy. 35 Patients with testicular cancer in whom both the para-aortic and ipsilateral iliac lymph nodes are irradiated, receive testicular radiation at doses of about 0.3-0.5 Gy, even when testicular shielding is provided. 36 After inhibition of spermato genesis for 6-8 months, gradual recovery of spermatogenesis takes place and pretreatment spermatogenesis is generally restored after 1-2 years, but might be incomplete or take several years in some patients. Factors favoring a more rapid and complete recovery of sperm-cell production are younger age and normal pretreatment sperm quality. 37 The amount of scattered irradiation is also important. If infradiaphragmatic radiotherapy is restricted to the para-aortic field, the median testicular radiation dose can be as low as 0.1 Gy, with no reduction in sperm counts 1 year after irradiation. 36 The long-term paternity rate for patients who underwent radiotherapy for testicular cancer is significantly lower than for patients followed by surveillance. 38 Huyghe et al. found radiotherapy to be more deleterious to subsequent fertility than chemotherapy in patients with testicular cancer, 39 but this has not been confirmed by other authors. 38, 40 Following radiotherapy for Hodgkin's lymphoma, there is a dose-dependent impairment of spermatogenesis. Normal spermatogenesis returns after 12-24 months in patients who receive scattered doses of less than 0.7 Gy. 41 High-dose pelvic radiotherapy can cause endothelial dysfunction and subendothelial thickening of the intima in the pelvic arteries 42 and microvessels responsible for penile blood flow. This might, in the long term, result in luminal stenosis and hypovascularization of the corpora cavernosa, thus partly explaining the increasing proportion of patients with ED several years after radiotherapy of the prostate. 43 Although the peripheral nerve system is usually regarded as relatively radio resistant, there is some evidence that high radiation doses can lead to lumbosacral plexopathies with resulting dysfunction of pelvic organs. 44 Total body irradiation is sometimes given as part of the conditioning regime before bone marrow transplant in patients with leukemia. Recovery of gonadal function has been reported in less than 20% of patients receiving this treatment. 45 A single, standard dose of the radioiodine 131 I, administered to thyroid cancer patients, can impair spermatogenesis only transiently. Permanent impairment, however, might be seen at high, cumulative doses, and semen cryopreservation should be considered for patients who are likely to require multiple administrations of 131 I. Overall, the risk of permanent infertility is considered low in patients receiving 131 I for thyroid cancer. 46 
GLOSSARY

B SYMPTOMS
Chemotherapy
As with the other treatments, a number of factors contribute to the risk of chemotherapy-related infertility. The choice and combination of cytostatic agents, the cumulative doses and the age of the patient all contribute to the risk of developing persistent postchemotherapy infertility (Table 2 ). Additive effects must be considered if cytostatic agents are combined with low dose testicular irradiation. The most gonadotoxic cytostatic agents are procarbazine and alkylating drugs, in particular cyclophosphamide.
Procarbazine has commonly been used in the treatment of Hodgkin's lymphoma as part of the MOPP (chlormethine, vincristine, pro carbazine, prednisolone) regime. A high proportion of patients who had been treated for Hodgkin's lymphoma with the MOPP combination developed persistent azoospermia. 47 The chemotherapy combination ABVD (doxo rubicin, bleomycin, vinblastine, dacarbazine) is now used to treat Hodgkin's lymphoma in preference to MOPP. ABVD is less gonadotoxic than MOPP, and most patients recover spermato genesis following treatment. 47 Postchemotherapy recovery of spermato genesis can be expected in 48% of testicular-cancer patients after 2 years, and in 80% by 5 years. 48 Postchemotherapy paternity is achieved in 64-75% of testicular-cancer patients attempting conception (Figure 2) . 38, 40 Huyghe et al. reported that the cumulative conception rate was about 85% in patients following chemotherapy for testicular cancer. 39 In male survivors of Hodgkin's lymphoma, the post-treatment paternity rate at 15 years was about 90% in those attempting paternity after supradiaphragmatic radiotherapy alone, compared to a post-treatment paternity rate of 58% in those that received additional chemotherapy (Figure 3) .
PREVENTION OF INFERTILITY
The process of preserving fertility in cancer patients starts with pretreatment discussion of issues relating to fertility with the cancer patient ( Figure 4) . Depending on the patient's age and circumstances, his partner or his parents might also be involved in the pretreatment discussion. The patient must recognize both the possibility of a cure for their cancer and the risk of infertility, and he has to be included in the final choice of therapy.
Prevention of treatment-related ejaculatory dysfunction and erectile dysfunction
The negative consequences of orchiectomy, in particular for patients with bilateral tumors, can be reduced by testis-conserving surgery in patients with small tumors. 31 Postponement of recommended testicular radiotherapy in patients having testis-conserving surgery, due to carcinoma in situ in the remaining testis, should be considered to allow repeated semen cryopreservation or natural conception.
During the last decade, nerve-sparing techniques have been introduced into the treatment of testicular cancer and cancer of the prostate, bladder and rectum. These techniques have reduced the percentage of patients with persistent postoperative and ejaculatory problems. After nerve-sparing RPLND, less than 10% of testicular cancer patients experience dry ejaculation. 49 Nerve-sparing radical prostatectomy preserves erectile function in up to 80% of the patients, depending on the selection of patients, 11, 24 with young age and an active sexual life before the operation being associated with the restoration of erectile func- 
Prevention of spermatogenesis arrest
There are no established pharmacologic methods that reduce the inhibition of spermato genesis during chemotherapy and radiotherapy. Although gonadotropin-releasing hormone analogs have shown promising results in rodents, they have not been effective in the clinical situation. 50 In young men, testicular shielding should always be considered during pelvic radiotherapy, to reduce the scattered irradiation dose to the testicles. 36 
Semen cryopreservation
Male cancer patients at risk of permanent and long-lasting post-treatment infertility, who do not rule out post-treatment paternity, should be offered cryopreservation of sperm cells. This should also be offered to men with high-grade oligospermia and those with azoospermia. In some men with azoospermia, sperm cells can be retrieved by testicular sperm extraction (TESE). 51 Ideally, semen cryopreservation should be performed before treatment is started, and, if possible, multiple samples should be preserved. Semen cryopreservation can also be considered after chemotherapy for patients in whom intensive cytotoxic treatment is planned because of tumor recurrence. Clinicians diagnosing testicular cancer should recommend that cryo preservation is performed before orchiectomy. 15 Although offering pretreatment semen cryopreservation has become routine in most cancer centers, only a minority of patients ever use their frozen semen, either because they do not attempt post-treatment paternity, or because they become fathers through natural conception or by using their oligospermic, posttreatment ejaculates for assisted reproductive techniques (ART). 38 
CONSIDERATIONS IN CHILDREN WITH A MALIGNANT DIAGNOSIS
Many authors have discussed the importance of considering the future fertility of children with cancer. Addressing such problems can be difficult, and differs from the approach described for adults because of the nature of the malignancies that typically occur in childhood, the stage of development the patient is in, and the pre maturity of the testes. Although initial reports suggested that the immature testis was relatively resistant to chemotherapy agents, 54 more recently it has become apparent that the prepubertal testis is not protected against the effects of cytotoxic treatment. 55 Production of sperm cells that are suitable for cryopreservation starts around the age of 12-13 years. 56 Deficiencies in plasma gonadotropins have been reported after cranial radiation doses of 35-45 Gy. These reduced levels of gonadotropins have been associated with reductions in sexsteroid concentrations and delayed puberty. 57 In contrast to previous experience, current treatment of children with acute lympho blastic leukemia is unlikely to result in infertility, because of the lower doses of cyclophosphamide and cytarabine that are now used.
In young, anejaculatory adolescents, sperm cells for cryopreservation might be obtained by electroejaculation under general anesthesia 58 or by TESE. 59 In even younger, prepubertal children, only experimental methods can be considered. Applying fertility-saving techniques in young children and adolescents raises considerable ethical problems. After appropriate counseling, written consent must be obtained from the parents of very young boys, whereas adolescents are most often able, and should be encouraged, to give consent themselves. Parents and adolescents should, however, be fully informed about the often experimental nature of the selected fertility-saving procedure.
MANAGEMENT OF POST-TREATMENT INFERTILE CANCER PATIENTS Assessment of patients with posttreatment infertility
The diagnostic work-up starts with the taking of patient history, including asking about ED or dry ejaculation, followed by a physical examination. A semen sample is mandatory, providing the patients are able to provide one. In patients with dry ejaculation, the postmasturbation urine should be investigated for the presence of sperm cells. Levels of serum FSH, LH, testosterone, and sexhormone-binding globulin, and preferably also levels of inhibin B, should be determined. There are no established treatments that can improve poor post-treatment spermato genesis in cancer patients. Exogenous testosterone is generally not indicated, as it suppresses the hypothalamicpituitary-gonadal axis and impairs spermatogenesis. 7 Hypogonadal men planning paternity Future paternity considered? Figure 4 Flow chart of preventive measures in the management of infertility in male cancer patients. Before treatment decisions can be made it is important that the adverse effects of treatment options on future fertility are discussed with the patient. The patient's partner or parents (in the case of children) might also wish to be involved in this discussion. In patients who do not wish to become fathers in the future, no particular fertility-preserving measures or semen cryopreservation are necessary. In men considering paternity in the future, treatments that are less gonadotoxic can be considered, and semen cryopreservation should be undertaken. Patients with pre-existing fertility problems, such as azoospermia or anejaculation, should be offered sperm retrieval techniques so that recovered sperm cells can be cryopreserved for future use. a In patients with suspected testicular cancer, fertility-preserving measures should be initiated before testicular surgery. TESE, testicular sperm extraction.
should postpone androgen supplementation until fertilization is achieved, as this treatment can further suppress spermato genesis. 60
Management of post-treatment infertility
Erectile dysfunction Oral PDE5 inhibitors or papaverin injections should be offered to patients with ED ( Figure 5 ).
The effect of such drugs depends upon whether the dysfunction is neurogenic, vasculogenic or psychogenic in origin. These ED treatments are least effective in patients with neurogenic impotence. One study found that 80% of patients who had undergone a bilateral nerve-sparing radical prostatectomy responded to treatment with PDE5 inhibitors in contrast to none of the patients who underwent non-nerve-sparing radical prostatectomy. 11 It is also important to remember that lower-than-normal levels of testosterone might be a contributing factor in such patients. If this is the case, cautious androgen supplementation can be considered by an endocrinologist; however, it is important to be aware of the risk of reduced spermatogenesis during exogenic testosterone application.
Dry ejaculation and azoospermia
Sympathicomimetic drugs should be used as a first-line treatment for patients experiencing anejaculation or retrograde ejaculation ( Figure 5 ). The success rate of these drugs is the same for cancer patients as for other men with dry ejaculation, but does vary with the type of sympathicomimetic drug and with the degree of impairment involved. Higher success rates are reported in men with retrograde ejaculation than in those with anejaculation. 61 Imipramine has been reported to reverse retrograde ejaculation in about 65% of men, 61 irrespective of which underlying disease caused the ejaculatory dysfunction. If treatment with sympathicomimetic drugs is unsuccessful, sperm cells can be obtained from post ejaculatory urine by TESE or by electroejaculation, and can be used for ART. 58, 59 In 15 testicular-cancer patients, sperma tozoa of sufficient quality for in vitro fertilization or intracytoplasmic sperm injection (ICSI) were obtained from 12 men by electroejaculation, resulting in nine pregnancies. 58 TESE should also be considered for men with azoospermia due to impaired spermato genesis ( Figure 5 ). Among 20 men with a history of cancer and chemotherapy, sperm were successfully extracted from 14 (70%). Of 12 couples in whom ICSI was subsequently performed, eight successfully became parents (including a pregnancy that was ongoing at the end of the study period). 62 
EXPERIMENTAL RESEARCH FOR PRESERVING AND RESTORING FERTILITY
Cryopreservation of semen obtained by masturbation has become the 'standard' fertility-saving method employed in most postpubertal males. Newer techniques for harvesting mature sperm cells for ART, such as microsurgical epi didymal aspiration and TESE, have been implemented in cases of disturbed semen transport or azoospermia. 59 Fertility-saving measures in pre pubertal boys, however, is the subject of ongoing research, 63 and preserving or restoring 'natural fertility' in adult cancer patients is also desirable.
In prepubertal boys, spermatogonial stem cells can be harvested from testis biopsies, and their single-cell solutions can be cryopreserved. After subsequent thawing, reinfused stem cells can be used to recolonize testicular tubules depleted of germ cells, for example, by oncologic treatment. 64 Ectopic xenografting or autografting of testicular tissue represents another experimental approach that could be used in the future to obtain mature sperm cells. In vitro maturation of testicular tissue, however, has not yet been successful in producing mature sperm cells. An alternative method involves the use of pluri potent embryonic stem cells, which might form germ cells in vitro. 65 This approach, if successful, would also circumvent the threat of transmission of cancer cells to the recipient if the pretreatment testicular tissue was contaminated by cancer cells before collection.
Although the application of gonadotropinreleasing hormone analogs and other hormones has failed to demonstrate protection of spermatogenesis in the clinical situation, further studies have been encouraged. It has been suggested that future trials should focus on hormonal treatment during, or shortly after, cancer treatment. This recommendation is based on data from rodents showing that arrest of spermatogonial differentiation occurs following cytotoxic treatment, rather than, or in addition to, stem-cell death. It has further been suggested from studies in rodents that intravascular testosterone and possibly FSH inhibit spermatogonal differentiation. Use of a hormonal treatment to suppress intratesticular testosterone might potentially lead to the restoration of spermatogonial differentiation. The actions of intratesticular testosterone and FSH, however, are required for normal spermatocyte and spermatid development. 66 Experimental methods for the preservation and restoration of postoperative erectile function are also being developed. Reconstruction and neuroprotection of the cavernous nerves are promising approaches that might help patients avoid postoperative ED. 24 
ETHICAL CONSIDERATIONS OF OFFERING ART TO PATIENTS
Whilst ART are promising, they raise ethical problems. So far, no increased risk of mal formations in the offspring of cancer patients has been found following natural conception. 67 Intracytoplasmatic sperm injection involves the injection of a single sperm directly into the oocyte, thus bypassing some of the selection mechanisms naturally involved in fertilization. Although ICSI has been associated with concerns for the future health of offspring conceived in this way, there is no evidence that these children have an increased number of malformations compared to the general population. 57 No consensus consists as to whether the use of cryopreseved semen is preferable to the use of post-treatment semen that has not been frozen. 68 Furthermore, both established and experimental ART are subject to national legislation that controls the use of such techniques.
CONCLUSION
Cancer and its treatment threaten male fertility and often reduce the chances of post-treatment paternity. This issue should be discussed with the patient prior to choosing and initiating treatment for cancer, and preventive measures should be considered in a multi disciplinary co-operation with oncologists, urologists, andrologists and those specializing in reproductive medicine. The application of fertility-preserving treatment is the first option, together with pretreatment sperm-cell cryopreservation (Figure 4) . The management of male cancer survivors who are infertile following treatment is directed by the cause of infertility ( Figure 5) , and often necessitates combined measures. With developing technology in mind, today's experimental techniques of harvesting gonadal tissue can be considered in young males; however, it is important to avoid giving these patients and their parents unrealistic expectations of future fertility.
KEY POINTS
■
Extensive pelvic or retroperitoneal surgery is often followed by erectile and/or ejaculatory dysfunction with subsequent fertility problems ■ Chemotherapy and infradiaphragmatic radiotherapy carry the risk of transiently or permanently impaired spermatogenesis ■ Semen cryopreservation should be offered to all men with cancer at risk of post-treatment infertility who are considering paternity ■ In males above the age of 12-13 years, mature sperm cells can be retrieved from the testes for cryopreservation by invasive procedures if they cannot be obtained by masturbation ■ Experimental approaches such as germ-cell transplantation and sperm-cell maturation in ectopic grafts sourced from testicular-tissue biopsies might enable very young patients to go on to become fathers ■ Future research with germ stem cells or embryonic stem cells will increase the number of options available for saving or restoring fertility in male cancer patients
